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Abstract: Several acridine derivatives were synthesized and their anti-proliferative activity 
was determined. The most active molecules were derivatives of 5-methylacridine-4-
carboxylic acid. The DNA binding properties of the synthesized acridines were analyzed 
by competitive dialysis and compared with the anti-proliferative activities. While inactive 
acridine derivatives showed high selectivity for G-quadruplex structures, the most active  
5-methylacridine-4-carboxamide derivatives had high affinity for DNA but showed poor 
specificity. An NMR titration study was performed with the most active 5-methylacridine-
4-carboxamide, confirming the high affinity of this compound for both duplex and 
quadruplex DNAs. 
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1. Introduction 
DNA-intercalating drugs are planar molecules composed by several fused aromatic rings that form 
stacks between DNA base pairs, thus reducing the opening and unwinding of the double helix. Each 
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intercalating drug binds strongly to particular base pairs as a result of several interactions, ranging 
from van der Waals forces to the formation of hydrogen bonds with adjacent nucleobases [1,2]. 
Telomeres are specialized DNA-protein structures at the termini of chromosomes crucial for 
chromosomal stability and accurate replication. Human telomeric DNA contains tandem repeats of the 
sequence TTAGGG. The guanine-rich strand can fold into four-stranded G-quadruplex structures 
involving G-tetrads, which are currently an attractive target for the development of anti-cancer  
drugs [3,4]. Acridine derivatives inhibit telomerase, presumably through their interaction with the  
G-quadruplex structures found in telomeric DNA [5,6]. A wide range of small molecules have been 
studied as quadruplex-binding and stabilizing ligands [7]. Most of these share common structural 
features, namely: (i) a planar heteroaromatic chromophore, which stacks by π-π interactions onto the  
G-quartet motif at the terminus of a quadruplex; and (ii) short alkyl chain substituents usually 
terminated by an amino group that is fully cationic at physiological pH. The precise nature of these 
substituents has been found to influence quadruplex affinity and selectivity [8,9]. 
Topoisomerase alters DNA topology through the decatenation and relaxation of supercoiled DNA [10]. 
By unwinding double-stranded DNA, this essential enzyme allows for normal cellular functions, such 
as replication and transcription [10]. DNA topoisomerases exist in various eukaryotic and prokaryotic 
forms [11] and are classified in two large groups named type I and type II. Topoisomerase-targeting 
anti-cancer drugs can be divided into two broad classes depending on their mechanism of action,  
either catalytic inhibitors or “topoisomerase poisons” [12]. The latter can be further subclassified into 
two groups: non-intercalating compounds, such as etoposide, and intercalators, like amsacrine and 
doxorubicin [13]. Intercalators act by forming ternary complexes with topoisomerases and DNA to 
inhibit re-ligation. However, the selectivity of intercalators for a particular DNA sequence is very low. 
Most often, selectivity is obtained from interactions of side-chain substitution in the major and minor 
grooves [14]. Another strategy to improve the selectivity of intercalating drugs is by linking several 
intercalating units. Various authors have described the synthesis of bis- or tris-intercalating drugs that 
show promising activity and selectivity [15–18]. 
The consensus is that acridine analogs target DNA through intercalation and disrupt enzyme 
recognition and/or association [19]. Acridine-4-carboxamides are a series of DNA intercalating 
topoisomerase poisons that show anti-tumor activity [20]. Among these, N-[2-(dimethylamino)ethyl]acridine- 
4-carboxamide (DACA) is a DNA-intercalating agent that inhibits both topoisomerase I and II [21] 
and is currently in phase II clinical trials. There are tight correlations between ligand structure, 
cytotoxicity and DNA-binding kinetics [22]. 
In the present study, we designed, synthesized and studied acridine and 5-methylacridine 
derivatives as potential anti-tumoral agents. During the selection of the acridine derivatives, we 
considered solid-phase methods for the preparation of the target compounds. Recently, we used 
peptide [23] and oligonucleotide chemistry [24] to prepare DNA-intercalating oligomers with several 
backbones for the assembly of a number of intercalating units. The modular character of solid-phase 
methods allows the rapid preparation of larger molecules that have G-quadruplex specific affinity [25,26]. 
The cytotoxicity of the acridine and 5-methylacridine derivatives to a tumoral cell line was assessed in 
MTT cell viability assays, thus identifying compounds exerting anti-tumoral activity. The DNA 
binding properties of the synthesized acridines were studied by competitive dialysis experiments. The 
affinity of the most active 5-methylacridine-4-carboxamide derivative to G-quadruplex telomeric and 
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duplex DNA sequences was further analyzed by NMR. This analysis confirmed the binding of this 
compound to both quadruplex and duplex DNA sequences. 
2. Results and Discussion 
2.1. Synthesis of the Acridine Derivatives  
We selected acridine-9-carboxylic acid (1) and 5-methylacridine-4-carboxylic acid (2) as starting 
compounds for the preparation of the new derivatives (Figure 1). Compound 1 is commercially 
available and has no anti-proliferative properties [24]. Compound 2 has been described as an 
intermediate in the synthesis of the bis-acridine derivatives of DACA [18]. Thus, in this study, we 
undertook the synthesis of compounds with this unit. Two types of derivatives were prepared. First, the 
replacement of the dimethylamino group of DACA for two residues of lysine (3) or arginine (4) was 
studied (Figure 2). These derivatives were prepared to check whether the protonable dimethylamino 
group can be replaced by amino acids with amino (Lys) or guanidino (Arg) groups. The synthesis of 
compounds 3 and 4 was performed by a standard solid-phase peptide approach using Fmoc-amino acids. 
After assembly of the dipeptide carboxylic acid 2 was coupled to the α-amino group of the dipeptides. 
Next we studied the possibility to generate compounds holding two units of the 5-methylacridine ring 
present in the 5-methyl derivative of DACA [18]. To join the units, we chose the L-threoninol 
backbone connected by phosphodiester links [27] for several reasons. The length of the threoninol 
linker is compatible with DNA structure and can be obtained in an enantiomerically pure form. 
Figure 1. Chemical structures of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide 
(DACA) and starting compounds 1 and 2. 
 
Figure 2. The acridine and 5-methylacridine derivatives synthesized in this study. 
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Threoninol has two distinct hydroxyl groups and one amino group. The intercalating agent can be 
attached at the amino group position, thus leaving the hydroxyl groups to build the backbone using 
standard solid-phase oligonucleotide methods [23,27]. To this end, the primary hydroxyl group of 
threoninol was protected by the 4,4′-O-dimethoxytrityl (DMT) group and the secondary alcohol was 
used to prepare the phosphoramidite derivative (Scheme 1). 
Scheme 1. Synthesis of the threoninol phosphoramidite derivative. 
 
Reagents and Conditions: i. Dimethoxytrityl chloride, DMAP, Pyr, o.n.; ii. O-2-cyanoethyl-N,N-
diisopropyl chlorophosphoramidite, DCM, DIEA, 0 °C then 25 °C for 1 h. 
For the synthesis of intercalating oligomers 7 and 8, the threoninol backbone was grown on solid-
phase, and then the intercalating agent was assembled on solid support. This strategy is more 
convenient for rapid synthesis, as it is unnecessary to construct each monomer with its intercalating 
agent, as described previously [23]. Here we report a hybrid synthesis. First, the phosphoramidite 
described above was assembled into a dimer (Scheme 2). 
Modified standard phosphoramidite chemistry was used. This consists of cycles of 3 chemical 
reactions: (1) removal of the DMT group with 3% trichloroacetic acid in dichloromethane;  
(2) phosphoramidite coupling using 10-fold excess of phosphoramidite and 40-fold excess of tetrazole 
and (3) oxidation of phosphite to phosphate with hydroperoxide solution in acetonitrile. The use of 
iodine for the oxidation of phosphites was avoided as we have previously observed some side  
products attributable to the premature removal of the Fmoc group. Also a capping reaction with acetic 
anhydride and N-methylimidazole was omitted in order to avoid the acetylation of the amino group 
observed in the synthesis of oligonucleotide-peptide conjugates using Fmoc-amino acids [28].  
To guarantee a high coupling yield, two consecutive phosphoramidite coupling reactions were 
systematically performed. Finally, Fmoc groups of threoninol were removed to allow coupling of 
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carboxylic acids 1 or 2, thereby providing the desired dimers 7 and 8 in satisfactory yields. Monomeric 
threoninol derivatives 5 and 6 were prepared as described [23]. 
Scheme 2. Solid-phase synthesis of acridine oligomers. 
 
Reagents and Conditions: (a) i. 20% piperidine, DMF, 30 min; ii. 5 eq. Trityl-O-(CH2)5COOH,  
5 eq. PyBOP, 10 eq. DIEA in DMF, 1 h; (b) i. 3% trichloroacetic acid in DCM, 10 min;  
ii. 10 eq. compound 11, 40 eq. tetrazole in acetonitrile, 10 min × 2; iii. 70% aq. tert-
butylhydroperoxide/acetonitrile (14:84 v/v), 10 min; (c) i. 20% piperidine, DMF, 30 min; ii. 5 eq. 
compound 1 or 2, 5 eq. PyBOP, 10 eq. DIEA in DMF, 1 h; iii. 3% trichloroacetic acid in DCM, 10 
min; iv. TFA 95%, 2 h. R = acridine (7) or 5-methylacridine (8). 
2.2. Cell Viability Assay  
The in vitro cytotoxicity of the compounds 1–8 was evaluated by colorimetric assays with a 
tetrazole salt (MTT) on the human colon carcinoma HBT38 cells. This assay is based on the capacity 
of living cells to incorporate and reduce the tetrazole salt. This reaction can be followed by the 
absorbance change of the reduced and oxidized forms. The reduction is observed only in living cells 
and the color intensity is directly correlated with the number of viable cells. The IC50 values for 
compounds 1–8 are given in Table 1. 
Table 1. Anti-proliferative activity: n.a. not active. 
Compound IC50 (µM) HBT38 
1 n.a. 
2 75 
3 n.a. 
4 n.a. 
5 n.a. 
6 60 
7 n.a. 
8 25 
The acridine derivatives 1, 5 and 7 did not show anti-tumoral activity. These results were expected 
as acridine-9-carboxylic acid [24] as well as 2-aminoethylglycine and aminoprolyl oligomers have no 
antiproliferative activity [24,25]. On the other hand, the 5-methylacridine-4-carboxylic acid derivatives 
2, 6 and 8 had moderate activity, dimer 8 being the most active compound. In contrast, the peptide 
derivatives 3 and 4 lost this activity. This is partially in agreement with the antiproliferative properties 
assigned to 5-methylacridine-4-carboxylic acid derivatives [17,18,20–22]. We expected some activity 
for peptide derivatives 3 and 4 because these compounds have a positively charged residue linked to 
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the carboxylic acid function as in the case of 5-methyl-N-[2-(dimethylamino)ethyl]acridine-4-carboxamide 
that have potent antitumor activity [21]. But in our study the addition of lysine and arginine residues 
instead of the N-dimethylaminoethyl group were detrimental for the antiproliferative activity. Also, 
literature reports that 5-substituted bis(acridine-4-carboxamide) derivatives have good anticancer 
activities [18]. In this work we observed the best antiproliferative activity for the dimer carrying two  
5-methylacridine-4-carboxamide units linked through threoninol phosphate backbone confirming the 
increase of activity by linking two DNA intercalating units. To our knowledge this is the first 
bisintercalating molecule linked by phosphate bonds with increased activity. In order to confirm that 
the activity may be mediated by DNA binding, competitive dialysis experiments were performed.  
2.3. Competitive Dialysis Studies  
To evaluate the selectivity and the affinity of intercalating derivates for DNA structures, we 
performed a competitive dialysis experiment using 11 nucleic acid structures [25]. The DNA 
sequences were selected to represent all the potential DNA structures that may be present at 
physiological pH: single-stranded, duplex, parallel and antiparallel triplexes and quadruplexes.  
As models for single-stranded structures, we used T20 and 24bclc. As duplexes, we used a  
self-complementary sequences Dickerson–Drew dodecamer (Dickerson) and a 26 mer (ds26). A 
parallel triplex (TC triplex) and an antiparallel triplex (GA triplex) were also prepared by mixing  
a hairpin Watson–Crick sequence and the corresponding triplex-forming sequence. Finally, the  
following G-quadruplex sequences were prepared: the tetramolecular parallel G-quadruplex TG4T [29]; the 
antiparallel thrombin-binding aptamer (TBA) [30]; the human telomere sequence (HT24) [31]; and the 
promoter sequences of c-myc (cmyc) [32] and bcl-2 (24bcl) [33]. The amount of bound ligand was 
directly proportional to the binding constant for each DNA structure [34,35]. Figure 3 shows the 
oligonucleotide affinity for each compound and Figure 3A the results for acridine and 5-methyl 
acridine carboxylic acids 1 and 2. Acridine-9-carboxylic acid 1 interacts only with duplex ds26, the 
methyl derivative 2 induced a change in the affinity showing also a triplex preference. While acridine 
derivatives 5 and 7 showed quadruplex selectivity, the methyl analogs 6 and 8 lost most of the 
selectivity, although they presented a higher affinity for most DNA sequences (Figures 3C,D). In 
contrast, the peptide derivatives 3 and 4 presented lower binding affinity for DNA (Figure 3B). 
Comparing the competitive dialysis results with the antiproliferative activity we can observe that the 
peptide derivatives 3 and 4 have both low affinity for any DNA molecule and no antiproliferative 
activity. Acridine derivatives 5 and 7 have interesting binding affinities for DNA quadruplex 
sequences but this affinity does not trigger inhibition of cell grown of HBT38 cancer cell lines. This is 
agreement with previous work on 2-aminoethylglycine and aminoprolyl acridine oligomers [24,25]. 
Finally, the most antiproliferative compounds 6 and 8 have a strong affinity for all type of DNA 
sequences. Although we cannot discard the hypothesis that the antiproliferative activity of these 
compounds is due to direct binding to proteins, we can hypothesize that the antiproliferative activity of 
these compounds may be mediated by DNA binding. This is in agreement with the inhibition of DNA 
topoisomerases described for this family of compounds [12,17,18,20–22]. 
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Figure 3. Competitive dialysis assay: The amount of ligand bound to each DNA structure 
is shown as a bar graph. 
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2.4. NMR Spectroscopy  
On the basis of cell viability studies the compound 8 demonstrated the highest anti-tumoral activity. 
Competitive dialysis experiments also show that compound 8 has affinity to all types of DNA 
sequences in spite of the presence of a negative phosphate backbone that may hinder binding with the 
DNA polyanionic molecule. As it is the first time that a bisintercalating molecule having a negatively 
charged phosphate backbone is shown to have DNA binding properties we confirmed that compound 8 
is able to bind to both duplex and quadruplex DNA molecules. First we tried the classical methods 
such UV- and fluorescence-based melting assays [36], fluorescence intercalator displacement  
assay [37], and mass spectrometry [38]. But any of these methods provide conclusive results and some 
of these methods were not compatible with the fluorescence properties of the acridine derivatives. For 
these reasons and in order to confirm the interaction with DNA, 8 was titrated into a solution of the 
quadruplex model (T2AG3)4 of the human telomere sequence and the resulting mixtures were analyzed 
by 1H-NMR. Similar experiments were performed with the starting carboxylic acid 2. T2AG3 is a  
short model sequence contained in the HT24 oligonucleotide. This oligonucleotide has been used  
previously for NMR characterization of drug binding on telomeric DNA sequences [39]. The short 
oligonucleotide has a more simple NMR spectrum than HT24 sequence, thus facilitating the study of 
the interactions of the drug with the DNA sequence. 
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The NMR spectra for the quadruplex showed three signals in the region of 10–12 ppm, belonging to 
Hoogsteen-bound guanine imino proton of the G quartets (Figure 4). During the addition of 8 to the 
quadruplex solution until reaching a ratio R = [8]/[(T2AG3)4] = 3, the imino proton signals caused by 
G4, G5 and G6 splits in the downfield-shifted region were related to the bound quadruplex form. This 
result confirms an 8 quadruplex interaction complex associated with drug toxicity. The imino protons 
signals were broad and disappeared at high R indicating that more than one species in equilibrium 
were present in solution (Figure 4). 
Figure 4. Imino proton region of (TTAGGG)4 resulting from the titration of the 
quadruplex with compounds 2 and 8. 
ppm ppm1112 11.5 11.0 10.5
Compound 2 Compound 8  
The oligonucleotide sequence 5′-CGATCG-3′ was used as model for a DNA duplex. In the region 
of 13–14 ppm, the NMR spectra of the duplex showed two signals, these belonging to imino proton of 
A3T4 and G2C5 (Figure 5).  
During the addition of 8 to the duplex solution until reaching the ratio  
R = [8]/[(CGATCG)2] = 1, the imino proton signals caused by G2 decreased the intensity of the signal, 
thereby indicating a preferred site of interaction at this level. The equivalent experiments with 
compound 2 showed slight differences. During the addition of 2 to the quadruplex solution until 
reaching the ratio R = [2]/[(T2AG3)4] = 3, the imino proton signals caused by G4, G5 and G6 split in 
the downfield-shifted region, thus indicating a binding interaction. In this case the imino proton signals 
were not broad at high R (Figure 4), indicating that only one bound species was present in the solution. 
Free quadruplex species structure was still present at this ratio. 
During the addition of 2 to the duplex solution until reaching the ratio R = [2]/[(CGATCG)2] = 1, 
the imino proton signal decreased in the intensity and was broad, suggesting the presence of multiple 
binding sites and complex equilibria (Figure 5). 
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Figure 5. Imino proton region of (CGATCG)2 resulting from the titration of the duplex 
with compounds 2 and 8. 
1314 ppm 14.0 13.0 ppm13.5
Compound 2 Compound 8  
In summary, NMR titration experiments confirm the interaction of compound 8 with both duplex 
and quadruplex DNA sequences, even when the quadruplex complex equilibria in solution were 
involved, whereas the interaction was more specific with the double helix, compound 2 showing the 
opposite behavior. 
3. Experimental  
3.1. Oligonucleotides and General Information  
Standard phosphoroamidites and reagents for DNA synthesis were purchased from Applied 
Biosystems and from Link Technologies. The synthesis of the oligonucleotides was performed  
at a scale of 1 μmol on an Applied Biosystem DNA/RNA 3400 synthesizer by solid-phase  
2-cyanoethylphosphoroamidite chemistry. The following sequences were prepared: T20: d(5′-TTT 
TTT TTT TTT TTT TTT TT-3′), 24bclc: d(5′-CCC GCC CCC TTC CTC CCG CGC CCG-3′), 
Dickerson: d(5′-CGC GAA TTC GCG-3′), ds26: d(5′-CAA TCG GAT CGA ATT CGA TCC GAT 
TG-3′), GA triplex : d(5′-GAA AGA GAG GAG GCC TTT TTG GAG GAG AGA AAG-3′) +  
d(5′-CCT CCT CTC TTT C-3′), TC triplex: d(5′-CCT CCT CTC TTT CCC TTT TTC TTT CTC TCC 
TCC-3′) + d(5′-GAA AGA GAG GAG G-3′), TG4T: d(5′-TGG GGT-3′), TBA: d(5′-GGT TGG TGT 
GGT TGG-3′), HT24: d(5′-TAG GGT TAG GGT TAG GGT TAG GGT-3′), 24bcl: d(5′-CGG GCG 
CGG GAG GAA GGG GGC GGG-3′) and cmyc: d(5′-GGG GAG GGT GGG GAG GGT GGG GAA 
GGT GGG G-3′). The resulting oligonucleotides were purified by HPLC and desalted in a Sephadex 
(NAP-10) G25 column. Acridine-9-carboxylic acid (1) was obtained from Aldrich and  
5-methylacridine-4-carboxylic acid (2) (Figure 1) was prepared following the strategy described 
previously [40]. Threoninol derivative (5) (Figure 2) was prepared following the literature [23]. NMR 
spectra were recorded on a Varian Mercury 400 (small compounds) or a Bruker AV-600 (oligo-
nucleotides) spectrometers. 
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3.2. Solid-Phase Synthesis of Peptide Derivatives 3 and 4  
Peptide derivatives 3, 4 were synthesized using Fmoc solid phase peptide synthesis.  
Fmoc-protected amino acids were obtained from Nova Biochem. The side chain of lysine was 
protected with the t-butoxycarbonyl (Boc) group and the arginine side chain was protected with the 
2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) group. Amino acids were assembled on  
4-(2',4'-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxy resin (Rink amide resin) solid support which 
allowed the cleavage in a single step treatment with 95% TFA, providing peptide amides in high yields 
and purities. Synthesis of amino acids derivatives: a cycle for each amino acid addition consisted of the 
following steps: (1) 20% piperidine in DMF; (2) 5% DIPEA in DCM; and (3) Fmoc-protected amino 
acid coupling with TBTU, HOBT and DIPEA catalysis then (1) 20% piperidine in DMF; (2) either 
compound 1 or compound 2 coupling with PyBOP, HOBT and DIPEA catalyst; and (3) cleavage with 
95% TFA. The compounds were analyzed by MALDI-TOF: 3 [M+] = 493.3 (expected 493.3) and 4 
[M+] = 549.3 (expected 549.3), and by HPLC obtaining a single peak of retention time 7.9 and  
8.2 min, respectively. Analytical HPLC was performed using an XBridge OST C18 (Waters) column (2.5 
µM, 4.6 × 5.5 mm) using a 10-min linear gradient from 9% to 45% B, and a flow rate of 1 mL/min; 
solution A was 5% ACN in 0.1 M aqueous TEAA, and B 70% ACN in 0.1 M aqueous TEAA. 
MALDI-TOF spectra were obtained using a Perseptive Voyager DETMRP mass spectrometer, 
equipped with a nitrogen laser at 337 nm using a 3 ns pulse. The matrix used contained  
2,5-dihydroxybenzoic acid (DHB, 10 mg/mL in water). 
3.3. N-((2S,3S)-1,3-Dihydroxybutan-2-yl)-5-methylacridine-4-carboxamide (6) 
5-Methylacridine-4-carboxylic acid (2, 100 mg, 0.42 mmol) was reacted with EDCI (121 mg,  
0.63 mmol), HOBt (85 mg, 0.63 mmol), L-threoninol (44 mg, 0.42 mmol) and 100 µL DIEA in DMF. 
Purification by chromatography on silica gel (10% methanol over AcOEt) yielded the compound 6  
(50 mg, 35%) as a foam. UV (max): 249, 343, 359 and 385 nm. Fluorescence spectra: exc: 385 nm, 
em: 433 nm. HPLC: a single peak of retention time 9.0 min. 1H-NMR, δH (400 MHz, CDCl3): 8.99 
(dd, 1H, J = 7.1 and 1.6 Hz), 8.87 (s, 1H), 8.15 (dd, 1H, J = 8.4 and 1.1 Hz), 7.90 (d, 1H, J = 8.4 Hz), 
7.65 (dd, 1H, J = 8.4 and 7.1 Hz), 7.50 (dd, 1H, J = 8. 4 and 7.0 Hz), 4.39–4.35 (m, 1H), 4.34–4.29 (m, 
1H), 4.16–4.08 (m, 2H), 2.96 (s, 3H), 1.35 (d, 3H, J = 6.4). [M+] = 324.8 (expected for C42H48N5O12P2 
324.4). 
3.4. Solid-Phase Synthesis of Acridine Oligomers 7 and 8  
The assembly of L-threoninol derivatives (7, 8) was carried out on Rink amide polystyrene solid 
support. An optimized oligonucleotide synthesis was used to build the main chain and then the 
intercalating agent was introduced (Scheme 2). Oligomer synthesis: a cycle for each L-threoninol 
backbone addition consisted of the following steps: (1) 3% trichloroacetic acid/dichlorometane;  
(2) coupling of compound 11 with tetrazole activation, 2 times; and (3) oxidation with 70% aq.  
tert-butyl hydroperoxide/acetonitrile (14:84 v/v) then (1) 20% piperidine in DMF; (2) either compound 
1 or compound 2 coupling with PyBOP, HOBT and DIPEA catalyst; (3) 3% trichloroacetic 
acid/dichlorometane; and (4) cleavage with 95% TFA. The compounds were analyzed by  
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MALDI-TOF: 7 [M+] = 876.8 (expected for C42H48N5O12P2 876.8), 8 [M+] = 905.4 (expected for 
C44H52N5O12P2 904.9) and by HPLC obtaining a peak of retention time 4.1 and 13.2 min, respectively. 
3.5. (9H-Fluoren-9-yl)methyl (2R,3R)-1-(bis(4-methoxyphenyl)(phenyl)methoxy)-3-hydroxybutan-2-
ylcarbamate (10) 
N-[(9H-Fluoren-9-yl)methyloxycarbonyl]-L-threoninol (compound 9, 500 mg, 1.53 mmol) was 
dissolved in anhydrous pyridine (10 mL) and reacted with 4,4′-O-dimethoxytriphenylmethyl chloride 
(1.84 mmol) and 4-dimethylaminopyridine (0.20 mmol, DMAP). The mixture was stirred at room 
temperature overnight. The reaction was quenched with methanol (0.5 mL) and the solvents were 
removed under reduced pressure. The residue was dissolved in dichloromethane (100 mL) and the 
organic phase was washed with saturated aqueous NaCl (50 mL). The solvent was evaporated and the 
residue was purified by chromatography on neutral aluminum oxide. The product was eluted with 
dichloromethane and 1% of methanol. The pure compound was obtained as an oil (733 mg, 76%).  
1H-NMR, δH (400 MHz, CDCl3): 8.55–6.77 (m, 21H), 4.45–4.33 (m, 3H), 4.22 (t, 1H, J = 7.0 Hz), 
4.08 (m, 1H), 3.76 (s, 6H), 3.43 (dd, 1H, J = 9.8 and 5.0), 3.25 (dd, 1H, J = 9.8 and 3.8 Hz), 1.16 (d, 
3H, J = 6.3 Hz). 13C-NMR, δC (100 MHz, CDCl3): 158.6; 158.5; 1475; 145.0; 144.1; 144.0; 139.6; 
130.1; 129.2; 128.3; 127.9; 127.7; 127.1; 125.2; 119.9; 113.2; 69.2; 68.9; 66.7; 58.4; 20.2; 19.5. 
3.6. (9H-Fluoren-9-yl)methyl (4R,5R)-7-(2-cyanoethoxy)-8-isopropyl-1,1-bis(4-methoxyphenyl)-5,9-
dimethyl-1-phenyl-2,6-dioxa-8-aza-7-phosphadecan-4-ylcarbamate (11)  
Compound 10 (1.1 mmol) was dried by evaporation with anhydrous ACN. The residue was 
dissolved in anhydrous DCM (20 mL) and diisopropylethylamine (DIEA) (4.6 mmol) was added under 
argon atmosphere. The solution was cooled to 0 °C in a ice bath and 2-cyanoethoxy-N,N-diisopropyl-
aminochlorophosphine (2.2 mmol) was added dropwise with a syringe. After the completion of the 
reaction, DCM (50 mL) was added and the organic layer was washed with saturated aqueous NaCl 
(100 mL). The solvent was evaporated under reduced pressure and the residue was purified by column 
chromatography on neutral aluminum oxide. The product was eluted with hexane/ethyl acetate 2:3. 
The desired compound was obtained (556 mg, 61%). 1H-NMR, δH (400 MHz, CDCl3): 7.77–6.80 (m, 
21H), 5.09 and 4.99 (d, 1H, J = 9.6 and 9.5 Hz, respectively, two isomers), 4.41–4.38 (m, 3H),  
4.36–4.29 (m, 2H), 4.22 (t, 1H, J = 7.0 Hz), 3.93–3.79 (m, 1H), 3.79 (s, 6H), 3.55–3.34 (m, 4H), 2.36 
(t, 2H, J = 6.3 Hz), 1.27–1.11 (m, 15H). 31P-NMR, δP (81 MHz, CDCl3): 148.88, 148.63 (phosphoric 
acid as external reference). 13C NMR, δC (100 MHz, CDCl3): 158.6; 158.4; 144.8; 144.9; 144.1; 144.0; 
136.0; 130.1; 130.0; 129.1; 128.3; 127.9; 127.7; 127.1; 127.0; 126.8; 125.1; 119.9; 117.6; 113.2; 69.0; 
68.9; 66.6; 58.4; 56.2; 55.2;43.2; 43.1; 24.7; 24.6; 24.4; 24.3; 20.3, 19.5; 19.4. 
3.7. Competitive Dialysis Assays 
Slide-A-Lyzer Mini Dialysis Units 3500MWCO were purchased from Pierce. A total 200 mL of the 
dialysate solution containing 1 μM of the compound was used for each competition dialysis assay. A 
volume of 100 μL of 50 μM monomeric unit of each of oligonucleotide sequence was placed in the 
Molecules 2012, 17 7078 
 
 
dialysis unit. Potassium phosphate buffer containing 185 mM NaCl, 185 mM KCl, 2 mM NaH2PO4,  
1 mM Na2EDTA and 6 mM Na2HPO4 at pH 7 was used for all experiments. 
The samples were allowed to equilibrate with continuous stirring at room temperature overnight. 
Dialysis samples were transferred to an Eppendorf tube. In order to measure the compound entered in 
the dialysis unit, dialysis samples were treated with a snake venom phosphodiesterase to release the 
intercalating compound as described previously [25]. 
Finally, the fluorescence of each sample was measured (λex and λem were set to 252 and 435 nm  
for compounds 1, 5 and 7 and to 258 and 460 nm for compounds 2, 3, 4, 6 and 8 and normalized for 
each compound. 
3.8. Cell Viability Assays 
The in vitro cytotoxicity of the compounds (1, 2, 3, 4, 5, 6, 7 and 8) was evaluated by colorimetric 
assays with a tetrazole salt (MTT) on the HTB-38 (human colon carcinoma) cell line. The cell line was 
cultured in RPMI and supplemented with 10% fetal calf serum and 200 mM L-glutamine. Cells were 
grown in a humidified atmosphere of air containing 5% CO2 at 37°. Cells were plated in triplicate 
wells (1.5 × 104 cells per well) in 100 µL of growth medium in 96-well plates and allowed to 
proliferate for 24 h. They were then treated with increasing concentrations of the compounds. After  
72 h incubation, 20 μM MTT (5 mg/mL in phosphate buffer saline 10%) was added for additional 4 h. 
Absorbance at 570 nm was measured on a multiwell plate reader after removing the medium and 
addition of 50 μL of dimethyl sulfoxide. Cell viability was expressed as a percentage of control and 
IC50 was determined as the concentration of the drug that produced 50% reduction of absorbance at 
570 nm. 
3.9. NMR Spectroscopy 
The NMR spectra of oligonucleotides were recorded at 25 °C on a Bruker AV-600 spectrometer 
equipped with a z-gradient triple resonance TXI and were processed with TOPSPIN v.1. The 
instrument was operated at a frequency of 600.10 MHz for 1H. 1H chemical shifts (δH) were measured 
in ppm and referenced to external DSS (sodium 2,2-dimethyl-2-silapentane-5-sulfonate salt) set for 
0.00 ppm. Estimated accuracy for protons is within 0.02 ppm. The samples for NMR measurements 
were dissolved in 500 μL H2O/D2O (9:1) containing 25 mM KH2PO4, 150 mM KCl and 1 mM EDTA 
(pH 6.7) for the quadruplex d(5′-TTAGGG-3′)4 and containing 10 mM KH2PO4, 70 mM KCl and  
0.2 mM EDTA (pH 7.0) for the double helix d(5′-CGATCG-3′)2. The final concentration of the 
oligonucleotide solutions ranged between 0.7 and 0.6 mM. A stock solution of 2 and 8 was prepared in 
DMSO-d6 at the concentrations of 10 and 20 mM, respectively.  1H-NMR titration was performed by 
adding increasing amounts of 2 and 8 to the oligonucleotide solutions at an R= [Ligand]/[DNA] ratio 
equal to 0, 0.25, 0.5, 0.75, 1, 2 and 3. 
4. Conclusions  
Several compounds with the 5-methylacridine-4-carboxamide core group present in a DNA 
intercalating dual topoisomerase I/II inhibitor (DACA) derivative were prepared and their  
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anti-proliferative properties were studied. Solid-phase methods were used for the rapid generation of 
the 5-methylacridine-4-carboxamide derivatives. As the protonable dimethylamino group was 
considered relevant for the biological activity [22], we first studied the replacement of this group by 
natural amino acids with protonable groups like lysine and arginine. Unfortunately, the resulting 
peptide-acridine compounds lost DNA binding capacity and thus were inactive. In contrast, the 
threoninol derivative carrying the 5-methylacridine-4-carboxamide unit retained the anti-proliferative 
properties of the 5-methylacridine-4-carboxylic acid. Linking two units of the 5-methylacridine-4-
carboxamide with a threoninol phosphate backbone generated the most active compound, in spite of 
the presence of the negative phosphate backbone. This finding demostrates that linking several 
intercalating units with a negative backbone may indeed be a useful strategy to obtain novel  
DNA-intercalating drugs as the DNA-binding properties are not negatively affected and compounds 
have increased solubility in aqueous solutions. 
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